A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06614192, led by AbbVie, and active but no longer recruiting on the registry. Official title: AndroMETa-CRC-064: An Open-Label, Randomised Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff. Planned enrolment is 74 participants (actual). The study started in 2024-11-08 and primary completion is expected in 2027-08. No results have been posted on ClinicalTrials.gov.